Notice NOT-DA-19-009 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-073 from the NIH Guide for Grants and Contracts

Notice NOT-DC-19-002 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Scientist Machine Learning - Bioinformatics Senior level, permanent, Immunology! A fantastic new opportunity has become available for a Bioinformatics Scientist specialising in Machine Learning to join a biopharma company in Baden-Wuerttemberg. Baden-Württemberg, Germany

Notice NOT-CA-19-011 from the NIH Guide for Grants and Contracts

Notice NOT-AG-18-045 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Bioinformatics Software Engineer Location: Cambridge, Cambridgeshire, England

Funding Opportunity RFA-DE-19-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Funding Opportunity RFA-DE-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Funding Opportunity RFA-CA-19-005 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote the creation of developing research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Developing Centers (under this FOA) and P50 Advanced Centers (companion RFA-CA-19-006).

Funding Opportunity RFA-CA-19-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote the development of advanced research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing, and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Advanced Centers (under this FOA) and P50 Developing Centers (companion RFA-CA-19-005).

DOE: Dana-Farber Cancer Institute: Dana-Farber Cancer Institute seeks a Research Fellow with expertise in computational biology . Boston, Massachusetts (US)

Notice NOT-CA-19-010 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-006 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Bioinformatics Post-Docs - Cancer Diagnostics Paramount have two fantastic opportunities for Bioinformatics/Comp Bio/Data Science/Statistical Genetic Cambridge, England

Notice NOT-AG-18-034 from the NIH Guide for Grants and Contracts

The Baliga Lab is seeking an outstanding Computational Biologist to join a leading edge effort to a unique opportunity for a computational biologist to work...
From Institute for Systems Biology - Wed, 14 Nov 2018 04:00:23 GMT - View all Seattle, WA jobs

Negotiable: Paramount Recruitment: Bioinformatics Team Leader - Target Discovery A renowned, multi-national Biopharmaceutical company is developing a global discovery sciences unit, fo Sweden

Funding Opportunity PA-19-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and clinical infectious diseases.

Funding Opportunity PA-19-066 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.